Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
French Innovative Leukemia Organisation
Initial treatment: 6 courses of CHOP-R 14 with evaluation of response before C4 (observation of no change or progression at this time will get the patient off study).
Consolidation : fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8).
Age
60–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \> 60 and \< 80 years
Non eligible for stem cell transplantation
CD20 diffuse large B-cell lymphoma according to the WHO classification
Bulky stage I and II \> ou =7 cm and stage III and IV
Leucocytes \> ou =3 G/l, granulocytes \> ou = 1,5 G/l, platelets \>ou= 100 G/L.
HIV negative
Written informed consent
You may not be if
Age \< 60 years and \> 80 years
Other types of lymphomas except CD20+ diffuse large B-cell lymphoma according to the WHO classification
Histologic transformation of low grade lymphoma (Involvement of the bone marrow by small B-cell lymphoma will not lead to exclusion of the patient)
Primary lymphoma of the central nervous system and transformed gastro intestinal MALT lymphoma
Meningeal involvement
Bone marrow involvement \> 25% after R-CHOP
Aggressive post-transplantation lymphoma
Absence of CD20 expression on tumor cells
Non bulky stages I et II
HIV positive
Active Hepatitis B or C
Left ventricular ejection fraction \< 50%.
Contra-indication to R-CHOP treatment
Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Participation at the same time in another study in which investigational drugs are used
Absence of written informed consent
Clareo Health | Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma
